Compare FRMM & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRMM | ACET |
|---|---|---|
| Founded | N/A | 1947 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 79.9M |
| IPO Year | 2017 | 2017 |
| Metric | FRMM | ACET |
|---|---|---|
| Price | $5.29 | $8.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 353.5K | 88.6K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $183.55 | N/A |
| Revenue Next Year | $166.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $0.46 |
| 52 Week High | $7.15 | $9.47 |
| Indicator | FRMM | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 48.39 |
| Support Level | $4.78 | $7.78 |
| Resistance Level | $5.60 | $8.68 |
| Average True Range (ATR) | 0.57 | 0.49 |
| MACD | -0.13 | -0.06 |
| Stochastic Oscillator | 11.11 | 32.62 |
Forum Markets Inc is a financial technology company focused on developing infrastructure that supports the origination, financing, and distribution of RWAs through blockchain-enabled capital markets. The company's business approach is centered on integrating traditional financial asset markets with blockchain-based infrastructure to enable the tokenization of income-generating real-world assets such as consumer credit, equipment finance assets, and other contractual cash-flow streams. It utilizes blockchain infrastructure, including Ethereum and related Layer-2 scaling protocols, to support the issuance, management, and potential secondary trading of tokenized financial instruments.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).